We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In our partnerships and licensing focus month, we speak with Mohammed Charki about his role at biotech Hemarina, and the company’s relationship with global drugmaker Sanofi. It’s fair to say ...

NEW YORK, Sept 23 (Reuters) - Sanofi's (SASY.PA), opens new tab chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

Sanofi Healthcare Bidders Revising Offers Over Talc Concerns CD&R, PAI look to exclude aspects of Gold Bond unit in bids Consumer business could be valued at €15 billion in a sale ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

Regeneron REGN1.05%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN-0.46%decrease; red down pointing triangle have won U.S. Food and Drug Administration expanded approval of ...

Sanofi named a new chief scientific officer this week, part of a series of moves that the drug company has argued will establish it as being more focused on research and development than in the past.

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...